Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-16 08:00:47 EDT

PhotosVideosAllPeople
LatestRanked
@tctmd.bsky.socialOct 16, 2026, 2:28 PM

Two novel incretin-based agents appear highly effective in type 2 diabetes, with the TRIUMPH-2 and SYNCHRONIZE-2 studies of #retatrutide and #survodutide, respectively, showing reductions in body weight and better glycemic control. https://bit.ly/4yQK8Ef

Photo, no description
@midgardfinance.comOct 5, 2026, 7:00 AM

💉 #obesity #EASD2026

🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.

All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/

Horizontal bar chart titled "Weight loss with type 2 diabetes": weight lost by adults with obesity and type 2 diabetes on the top dose of six drugs, each beside its own trial's placebo, counting all randomised patients. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 18.8% against 5.1% on placebo. Tirzepatide 15 mg (SURMOUNT-2, 72 weeks): 14.7% against 3.2% on placebo. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 13.7% against 3.4% on placebo. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 13.2% against 3.9% on placebo. Survodutide 6.0 mg (SYNCHRONIZE-2, 76 weeks): 9.8% against 3.9% on placebo. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 9.6% against 2.5% on placebo. Retatrutide and survodutide, the two trials read out at the EASD congress, are drawn in purple and the other four in grey. These are separate trials of 68 to 80 weeks, not a head-to-head comparison.
@midgardfinance.comOct 1, 2026, 12:30 PM

💉 #obesity #EASD2026

🇩🇪 Boehringer's #survodutide, from 🇩🇰 Zealand, in obesity with type 2 diabetes. Phase 3, NEJM:

Weight, all randomised: -9.8% vs -3.9% placebo
On treatment: -13.1%
Stopped for side effects: 26% vs 9%. Four rivals: 6-11%

midgardfinance.com/obesity/drugs/survodutide/

$ZEAL

Scatter chart of five obesity drugs in their phase 3 trials in adults with obesity and type 2 diabetes, one point per drug at its top dose. Across: the share of patients who stopped the drug because of side effects. Down: average weight change counting all randomised patients. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 6 per cent stopped, weight -13.2 per cent. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 7 per cent stopped, weight -18.8 per cent. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 8 per cent stopped, weight -13.7 per cent. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 11 per cent stopped, weight -9.6 per cent. Survodutide 6 mg (SYNCHRONIZE-2, 76 weeks): 26 per cent stopped, weight -9.8 per cent. Four of the points sit between 6 and 11 per cent stopping; survodutide is alone on the right at 26 per cent, with about the same weight loss as the oral drug orforglipron. Survodutide's trial was published in the New England Journal of Medicine on 1 October 2026. These are separate trials with different participants and lengths, not a head-to-head comparison. Tirzepatide is not shown because its trial's published summary gives no comparable figure for stopping.